Quantitative trading software built around the retatrutide catalyst sequence.

Tretidal is a software product licensed to sophisticated users for use in their own trading. It is not a financial product within the meaning of the Corporations Act 2001 (Cth), it is not a managed investment scheme, and it does not constitute financial product advice, personal advice, or general advice. Tretidal does not hold, custody, or execute against user funds. Users are solely responsible for the trading decisions they make using the software and for the outcomes of those decisions. Nothing on this website constitutes an offer of financial services or an inducement to acquire a financial product. Prospective users must consult their own independent legal, financial, and tax advisers before licensing or using the software.

Access to Tretidal is granted under a written software licence agreement, to sophisticated users only, at Tretidal Pty Ltd's sole discretion. Access requires completion of onboarding, acceptance of the licence terms, and payment of the applicable setup and subscription fees. Tretidal reserves the right to refuse or withdraw access for any reason. The licence is non-exclusive, non-transferable, and terminable in accordance with its terms. No part of the software, model output, proprietary dataset, or underlying reasoning may be redistributed, resold, sublicensed, published, or reverse engineered. Tretidal Pty Ltd does not hold an Australian Financial Services Licence and does not require one to license software; it does not provide financial product advice, dealing, or managed discretionary account services.

Signals, catalyst scores, position sizing suggestions and reasoning generated by Tretidal are the output of a proprietary model based on data available at the time of generation. Model outputs are provided for user consideration only. They are not recommendations, projections, or guarantees of future performance, and users must independently verify all model outputs before acting on them. All analyst price targets referenced on this website (including those attributed to Morgan Stanley, Goldman Sachs, Leerink Partners, Bernstein, and others) are sourced from publicly available third party research and represent those analysts opinions as at the dates indicated. They are not Tretidal's projections and should not be interpreted as such. These targets may change without notice and may not be achieved. This website also contains forward looking statements regarding market size, clinical trial outcomes, and regulatory timelines. These involve substantial risks and uncertainties that may cause actual outcomes to differ materially. Past performance of any asset or strategy is not indicative of future results.

Trading equities, options and derivatives involves substantial risk of loss, including the potential loss of all capital deployed. The value of positions can go down as well as up. Users who act on Tretidal model outputs do so in their own brokerage accounts, under their own control, and entirely at their own risk. Tretidal makes no guarantee that use of the software will produce positive returns. Specific risks include but are not limited to: clinical trial failure or delay, regulatory rejection, model degradation, software or data malfunction, cybersecurity breach, market volatility, liquidity constraints, execution slippage, brokerage counterparty risk, and changes in law or regulation. Users should not trade with capital they cannot afford to lose, and are responsible for compliance with all applicable tax, regulatory and reporting obligations in their jurisdiction. This website does not purport to contain all information a prospective user may require. Any indicated backtest figures are hypothetical results from applying the Tretidal strategy to historical Eli Lilly daily price data. Hypothetical performance has inherent limitations.